NCT06973096
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentUniversity of PennsylvaniaInvestigator-initiated
~9 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:CART-EGFR-IL13Ra2 cellsRituximab or Rituximab biosimilarFludarabine + Cyclophosphamide combination
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Measured over Up to 15 years following CART-EGFR-IL13Ra2 administration
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Stephen Bagley, MD, MSCE · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V5.0Up to 15 years following CART-EGFR-IL13Ra2 administration
Type, frequency, severity, and attribution of adverse events
- Occurrence of treatment-limiting toxicities (TLTs)28 days post-CAR T cell administration